Proliferative Glomerulonephritis With Fibrils, Monoclonal κ Light Chain, and C3 Deposits.

B-cell disorder C3 glomerulopathy Case report Complement Fibrils Immunotactoid Kidney biopsy Light chain Membranoproliferative glomerulonephritis (MPGN) Monoclonal gammopathy of renal significance (MGRS) Multiple myeloma PGNMID

Journal

American journal of kidney diseases : the official journal of the National Kidney Foundation
ISSN: 1523-6838
Titre abrégé: Am J Kidney Dis
Pays: United States
ID NLM: 8110075

Informations de publication

Date de publication:
09 2021
Historique:
received: 06 07 2020
accepted: 07 01 2021
pubmed: 29 3 2021
medline: 14 9 2021
entrez: 28 3 2021
Statut: ppublish

Résumé

There is increasing recognition of monoclonal gammopathy as a cause of proliferative glomerulonephritis (GN), including cases in which glomerular deposition of monoclonal immunoglobulin is demonstrated. Recently, proliferative GN with monoclonal immunoglobulin deposits (PGNMID) has incorporated a light chain variant of the disease (termed PGNMID-LC). Intriguingly, glomerular co-deposition of C3 is found in addition to monotypic light chain, implying complement activation via the alternative pathway (AP). We present a unique case of proliferative GN in a 42-year-old man who presented with nephrotic syndrome and was found to have κ light chain multiple myeloma. Immune staining of the glomerulus was positive only for κ light chain and C3, with the striking appearance of nonamyloid fibrils on electron microscopy. Following clonally targeted therapy for myeloma, the renal clinical abnormalities resolved completely. We present detailed molecular studies for light chain and complement and consider local mechanisms whereby monoclonal κ light chain fibrils may have triggered AP activation within the glomerulus.

Identifiants

pubmed: 33774080
pii: S0272-6386(21)00499-6
doi: 10.1053/j.ajkd.2021.01.014
pii:
doi:

Substances chimiques

Complement C3 0
Immunoglobulin G 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

459-463

Informations de copyright

Copyright © 2021 National Kidney Foundation, Inc. All rights reserved.

Auteurs

Adam G Steinberg (AG)

Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia. Electronic address: adam.steinberg@mh.org.au.

Lucy C Fox (LC)

Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.

Sebastien Bender (S)

Centre National de la Recherche Scientifique UMR CNRS 7276/INSERM U1262, Université de Limoges, Limoges, France.

Ahida Batrouney (A)

Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia.

Surender Juneja (S)

Department of Hematology, Royal Melbourne Hospital, Parkville, Victoria, Australia.

Christophe Sirac (C)

Centre National de la Recherche Scientifique UMR CNRS 7276/INSERM U1262, Université de Limoges, Limoges, France.

Guy Touchard (G)

Service de Néphrologie, Hémodialyse et Transplantation Rénale, CIC INSERM 1402, Centre de référence pour l'amylose AL et autres maladies par dépôt d'immunoglobulines monoclonales, CHU Poitiers, Poitiers, France.

Piers Blombery (P)

Peter MacCallum Cancer Centre, Parkville, Victoria, Australia.

Moira J Finlay (MJ)

Department of Anatomical Pathology, Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.

Frank Bridoux (F)

Centre National de la Recherche Scientifique UMR CNRS 7276/INSERM U1262, Université de Limoges, Limoges, France; Service de Néphrologie, Hémodialyse et Transplantation Rénale, CIC INSERM 1402, Centre de référence pour l'amylose AL et autres maladies par dépôt d'immunoglobulines monoclonales, CHU Poitiers, Poitiers, France.

Thomas D Barbour (TD)

Department of Nephrology, Royal Melbourne Hospital, Parkville, Victoria, Australia; Department of Medicine, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH